Related Experiment Video

Updated: Oct 1, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

Insights on ErbB glycosylation - contributions to precision oncology

Henrique O Duarte1, Celso A Reis2, Joana Gomes1

  • 1i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135, Porto, Portugal; IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, 4200-135, Porto, Portugal.

Trends in Cancer
|March 9, 2022
PubMed

Insights

Understanding ErbB receptor glycosylation is key to overcoming therapeutic resistance in cancer. Mapping the ErbB glycome will improve drug design and patient stratification for better cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Glycobiology

Background:

  • ErbB receptors are crucial in cancer development.
  • Resistance to ErbB-targeted therapies is a major clinical challenge.
  • Post-translational glycosylation of ErbB receptors influences their function and therapeutic response.

Purpose of the Study:

  • To investigate the site-specific glycome of ErbB receptors.
  • To understand how glycosylation impacts ErbB receptor structure and function.
  • To identify strategies for overcoming therapeutic resistance.

Main Methods:

  • Site-specific analysis of ErbB receptor glycosylation.
  • Structural and functional characterization of glycosylated ErbB receptors.
  • Bioinformatic analysis of glycomic data.

Main Results:

  • Detailed mapping of ErbB receptor glycosylation sites.
  • Identification of key glycosylation patterns affecting receptor activity.
  • Insights into mechanisms of therapeutic resistance driven by glycosylation.

Conclusions:

  • Elucidating the ErbB glycome is essential for developing next-generation therapeutics.
  • Targeting glycosylation may overcome resistance to ErbB-directed therapies.
  • Glycosylation patterns can serve as biomarkers for patient stratification and treatment guidance.
Keywords:
ErbBglycosylationreceptor tyrosine kinasetargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K